Project Grant R43CA141887

The National Institute of General Medical Sciences (NIGMS) awarded a $700,000 Project Grant under the Biomedical Research and Research Training Program (CFDA 93.859) to Mirimus, Inc., a small disadvantaged business located in Brooklyn, NY. The grant supports the development of next-generation RNA interference (RNAi) therapeutics and the creation of an in vivo model to evaluate their efficacy and biodistribution. Specifically, the project aims to generate a murine "Optimus Model"...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) supports the development of an enzyme-free, label-free quantitative microarray technology for measuring target nucleic acid binding to single-stranded DNA probes. The research aims to design a "perfect switch" binary probe system that generates a redox signal upon target binding, enabling quantification of small nucleic acids...

This Project Grant award of $390,290.00 from the National Cancer Institute under the Cancer Biology Research (CFDA 93.396) program supports research to study the role of microRNA isoforms (miRNA modifications) as potential cancer biomarkers and uncover broader miRNA regulation in cancer. The award period runs from June 1, 2024 to May 31, 2026. The key products/services to be delivered include: Functional analysis and post-transcriptional regulation of the broader miRNA landscape in cancer,...

The National Human Genome Research Institute (NHGRI), through its Human Genome Research program (CFDA 93.172), has awarded a $352,929 Project Grant to Ribo-Therapeutics LLC to develop and validate a novel platform for the enrichment and profiling of circular RNAs (circRNAs). The goal is to create a "quick, robust, and unbiased" technology for isolating and characterizing the full repertoire of circRNAs, which have been implicated in various diseases but are challenging to study with...

This Project Grant award of $273,974 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, supports the development of Kasa Bio, L.L.C.'s novel ZIP-MELT multiplex miRNA solution for liver disease screening. The key product being developed is a cost-effective, eco-friendly RT-qPCR-based technology that can detect multiple miRNA biomarkers from various sample matrices in a single workflow. This solution aims to...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $2,884,842 to the Icahn School of Medicine at Mount Sinai to develop new therapies for genetic disorders affecting the RAS/MAPK signaling pathway, known as "rasopathies". The research aims to: 1) identify the protein targets of the drug candidate rigosertib and a new compound called M1 in rasopathy models; 2)...

The National Institute of General Medical Sciences (NIGMS) awarded a $307,257 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to Sxrna Technologies, Inc. to develop a rapid cloning technology called "SXRNA-SELECT" that aims to decrease the time required to clone mammalian cells and increase protein yields for biotherapeutic production. The key objectives are to: 1) optimize the delivery protocol for plasmids and SXRNA-bait, 2) demonstrate selection for...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) aims to elucidate the role of mitochondrial function in Rasopathies, a spectrum of rare genetic disorders affecting the Ras/MAPK signaling pathway. The $466,125 award to New York University (NYU) School of Medicine will fund a 2-year research project to analyze mitochondrial morphology and function in tissues...

The National Institute of General Medical Sciences (NIGMS) awarded Attogene Corporation, a biotechnology company based in Austin, Texas, a $229,975 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to develop a rapid, portable, and sensitive test for detecting ribonucleases (RNases). The grant supports the company's efforts to create a novel lateral flow assay prototype that can quickly identify RNase contamination, which is critical for ensuring quality...

This $256,000 National Science Foundation Engineering grant supports the development of an easy RNA adenylation method for deep sequencing of picogram RNA samples with high resolution. Specifically, Ezrabio Inc. will develop a versatile and cost-effective library construction technology that enables protein translation monitoring on a variety of biological samples. The proposed technology relies on a novel enzyme system capable of 5' adenylation and 3' polyadenylation of RNA fragments to...